Copyright
©2010 Baishideng. All rights reserved.
World J Gastroenterol. Jul 28, 2010; 16(28): 3592-3596
Published online Jul 28, 2010. doi: 10.3748/wjg.v16.i28.3592
Published online Jul 28, 2010. doi: 10.3748/wjg.v16.i28.3592
Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib
Christina Wich, Deike Strobel, Thaddäus Till Wissniowski, Matthias Ocker, Department of Medicine I, University Hospital Erlangen, Ulmenweg 18, 91054 Erlangen, Germany
Abbas Agaimy, Arndt Hartmann, Department of Pathology, University Hospital Erlangen, Krankenhausstr. 12, 91054 Erlangen, Germany
Matthias Ocker, Institute for Surgical Research, Philipps University Marburg, Baldingerstrasse, 35033 Marburg, Germany
Author contributions: Wich C and Agaimy A contributed equally to this work; Wich C, Agaimy A, Strobel D, Wissniowski TT, Hartmann A and Ocker M performed the research; Wich C and Ocker M analyzed the data and wrote the paper.
Correspondence to: Christina Wich, MD, Department of Medicine I, University Hospital Erlangen, Ulmenweg 18, 91054 Erlangen, Germany. christina.wich@uk-erlangen.de
Telephone: +49-9131-8535000 Fax: +49-9131-8535209
Received: January 14, 2010
Revised: March 15, 2010
Accepted: March 22, 2010
Published online: July 28, 2010
Revised: March 15, 2010
Accepted: March 22, 2010
Published online: July 28, 2010
Abstract
The overall survival for patients with advanced hepatocellular carcinoma (HCC) is still limited. Although the multi-kinase inhibitor sorafenib has recently been approved for this disease, response rates are still low and patients often face dose-limiting toxicities which lead to a reduction in prognosis and treatment success. We here report a patient with metastasized HCC who shows a sustained response for more than 30 mo to sorafenib therapy after failure of a first line therapy with gemcitabine, oxaliplatin and bevacizumab.
Keywords: Hepatocellular carcinoma; Sorafenib; Bevacizumab; Angiogenesis